TrialAssure launches TrialResults.com
TrialAssure launches TrialResults.com TrialAssure, a global software company focused on developing clinical trial transparency tools, has announced the launch of TrialResults.com, a new portal for sponsors to publicly share plain language, or lay, summaries with clinical trial participants. This portal allows trial participants to access the plain language summaries in any region of the world and in their native language.
In place of mailing paper copies of the plain language summaries to participants, sponsors can upload the summary onto the portal.
Using TrialResults.com takes just three steps:
- Clinical research organizations and sponsors upload completed plain language summaries onto the portal
- Users enter the unique trial identifier that has been provided to them into the search bar
- The relevant plain language summary appears
Currently, only 2 percent of clinical trial sponsors have issued plain language summaries to participants in the past few years, as recently reported by Applied Clinical Trials.
“TrialResults.com comes at a crucial time in the pharmaceutical industry when the requirement for posting lay summaries is looming,” said Alan Nicolle, Director, Business Development & Business Alliance Partnerships at TrialAssure in London.
Learn more at www.trialresults.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
